Skip to main content

Aliquots Archives

Calculating risk for uterine fibroids

Apr. 26, 2022—Vanderbilt researchers have constructed a polygenic risk score for uterine fibroids that will be useful for exploring causes of these benign tumors and identifying novel drug targets and therapies.

Read more


Molecular testing across tumor types

Apr. 25, 2022—The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets.

Read more


When science spills onto social media

Apr. 21, 2022—Vanderbilt researchers report that social media posts can offer insights into how the public feels about genome editing, with stances varying across platforms and differing from those of academics and policy makers.

Read more


Youthful healing for burn wounds

Apr. 21, 2022—Topical treatment of burns with an immunosuppressive drug counteracted the negative effects of aging on wound healing, Vanderbilt researchers have discovered.

Read more


Financial impact of prior authorization

Apr. 12, 2022—Prior authorization — health insurer approval of a medical intervention prior to treatment — costs more than $40 million for U.S. academic radiation oncology practices, with questionable value added to patient care.

Read more


Peptides promote AFib arrhythmia

Apr. 11, 2022—Peptide oligomers have detrimental metabolic effects and cause pro-arrhythmic electrophysiological changes in heart atria, suggesting they may contribute to atrial fibrillation.

Read more


Computer eyeballs graft-vs-host disease

Apr. 7, 2022—A machine learning algorithm identified areas of skin affected by chronic graft-versus-host disease on par with clinicians, opening the door to streamlining and standardizing this measure of patient response to therapy.

Read more


New prognosis predictor and target for gastric cancer

Apr. 7, 2022—The protein CGA — a subunit of glycoprotein hormones — is a biomarker that predicts chemoresistance in gastric cancer and could be targeted along with EGFR to restore chemosensitivity.

Read more


There’s no slowing arterial stiffening

Mar. 29, 2022—Over 10 years, multiple healthy behaviors did not slow the progression of arterial stiffness, a risk factor for coronary artery disease, hypertension, stroke, atrial fibrillation and heart failure.

Read more


Rheumatoid arthritis: special deliveries

Mar. 28, 2022—Birth outcomes including postpartum infection and blood transfusion were similar in women with and without rheumatoid arthritis, and continued use of disease-modifying antirheumatic drugs and biologics is recommended to limit steroid exposure.

Read more


Stress in young adult cancer patients and caregivers

Mar. 24, 2022—Adolescent and young adult oncology patients and caregivers experience psychosocial impairment and financial toxicity at the time of cancer diagnosis, findings that will inform interventions to support patient and caregiver well-being.

Read more


Reducing obesity-related inflammation

Mar. 24, 2022—A treatment that increases levels of lipid signaling molecules reduced adipose tissue inflammation in obese adults, suggesting this pathway may be a valuable target for modulating fat and systemic inflammation.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more